The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday, as they were criticized for charging way more for some “critical” prescription drugs than it cost them.
FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%
